v3.25.4
Consolidated Statements of Income (Loss) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Income Statement [Abstract]    
Revenue $ 559 $ 43,258
Cost of sales (215) (11,810)
Gross profit 344 31,448
Research and development costs (67,753) (67,883)
General and administrative expenses (22,344) (26,884)
Restructuring charges (1,324) 0
Operating loss (91,077) (63,319)
Foreign currency (loss)/gain, net (8,467) 646
Other income, net 3,480 4,472
Benefit from R&D credit 7,463 13,737
Loss before income tax expense (88,601) (44,464)
Income tax expense (11) (845)
Net Loss $ (88,612) $ (45,309)
Loss per share basic $ (0.63) $ (0.33)
Loss per share diluted $ (0.63) $ (0.33)
Weighted-average shares outstanding basic 141,694,702 138,752,224
Weighted-average shares outstanding diluted 141,694,702 138,752,224